Indivior PLC Ordinary Share INDV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
-
Indivior Announces BARDA's First Order of OPVEE® to Combat Opioids and Aid in National Preparedness
-
Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame
-
Indivior Announces Q2 2024 Financial Results
-
Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT
-
Indivior Says UK High Court Strikes Claims Against It and Reckitt Benckiser
Trading Information
- Previous Close Price
- GBX 746.50
- Day Range
- GBX 744.50–788.00
- 52-Week Range
- GBX 653.00–1,770.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 101.92 Bil
- Volume/Avg
- 441,928 / 783,470
Key Statistics
- Price/Earnings (Normalized)
- 3.70
- Price/Sales
- 1.20
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 6.95%
Company Profile
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,164
- Website
- https://www.indivior.com
Comparables
Valuation
|
Metric
|
INDV
|
KNSA
|
AZN
|
|---|---|---|---|
Price/Earnings (Normalized) | 3.70 | 222.43 | 20.47 |
Price/Book Value | — | 4.00 | 5.82 |
Price/Sales | 1.20 | 5.17 | 4.70 |
Price/Cash Flow | — | 70.86 | 21.77 |
Price/Earnings
INDV
KNSA
AZN
Financial Strength
|
Metric
|
INDV
|
KNSA
|
AZN
|
|---|---|---|---|
Quick Ratio | 0.65 | 2.84 | 0.69 |
Current Ratio | 0.85 | 3.57 | 0.89 |
Interest Coverage | −5.25 | — | 5.45 |
Quick Ratio
INDV
KNSA
AZN
Profitability
|
Metric
|
INDV
|
KNSA
|
AZN
|
|---|---|---|---|
Return on Assets (Normalized) | 12.96% | 2.27% | 57.63% |
Return on Equity (Normalized) | — | 2.73% | 151.23% |
Return on Invested Capital (Normalized) | 80.49% | 2.66% | 84.88% |
Return on Assets
INDV
KNSA
AZN
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Qbmpxqmym | Fsjc | $86.1 Bil | |||
| Merck KGaA ADR
MKKGY
| Wbjvxdgghv | Tmlzkb | $74.3 Bil | |||
| Haleon PLC ADR
HLN
| Thjfwzmvf | Ftf | $45.9 Bil | |||
| Viatris Inc
VTRS
| Gvhpfdzj | Xzfz | $13.8 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Ztpdqvq | Xqyx | $13.2 Bil | |||
| Catalent Inc
CTLT
| Mfwsbttbb | Hgyqhpw | $11.0 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Kdqdlpw | Rsslyx | $3.4 Bil | |||
| Perrigo Co PLC
PRGO
| Rdhjdxhs | Zbkb | $3.4 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Dvbgxtzly | Lcd | $2.4 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Bvcbxfd | Rmy | $2.2 Bil |
United States